LOS ANGELES, CALIFORNIA – March 25, 2021 – GTX Corp (OTC: GTXO) (“GTX” or the “Company”), a pioneer in the field of wearable GPS human and asset tracking systems and a supplier of Health and Safety personal protective medical equipment “PPE”, announced today it will start exporting its Rapid Diagnostic Test-Kits for Antigens and Antibodies, along with hearing related products to distributors in the United Kingdom.
GTX has built a network of partners that have been distributing many of its products through B2B Healthcare and Telehealth providers across Europe which supply, install and support Electronic Assistive Technology products and systems to the National Health Services and enabled care and support markets.
Phil Iles, Possum Sales Manager for UK & EIRE, stated “Since we originally launched the GPS SmartSoles and GPS Take-Along Tracker in the UK, we have been keen to explore other health & safety products from GTX. Possum only adds the most reliable and innovative equipment to our product portfolio which we believe will help people gain greater independence whilst providing loved ones with peace of mind. We believe adding hearing assisted technology to our current product line is a great addition to our growing product range.”
GTX entered the Hearing Health market in early 2020, right before COVID hit, with the launch of the patented noise reduction ear buds or NRBz, designed to reduce loud background noise by up to 40 dB’s, and now through its recently signed collaboration and reseller agreement with InnerScope Hearing Technologies, Inc. (OTC: INND) GTX will spearhead the international distribution for the hearing related products. Hearing loss from noise is the second most reported occupational illness for industrial workers. Close to 30 million people are exposed to dangerous noise in the US workplace, costing billions in treatments and lost productivity, the Veterans Association spends close to $1 billion a year in hearing loss disability payments.
Matthew Moore, CEO of InnerScope Hearing Technologies Inc., commented, “We are proud to have partnered with GTX to offer our latest in Direct-to-Consumer Bluetooth App-Controlled Hearing Assistive Devices and related hearing health products. GTX’s Health and Safety Products, especially its personal hearing protection product NRBz, is right in line with InnerScope’s approach of offering Direct-to-Consumer Hearing Health Products. We believe our Hearing Products will be well received by GTX’s network of domestic and international distribution partners.
GTX has also begun working with other international partners and distributors to export its COVID-19 Rapid Antigen and Antibody Test-Kits. “We have one distributor in the UK already lined up and in discussions with several more across Europe and Canada,” stated Patrick Bertagna GTX Corp CEO.
GTX distributes an extensive line of wearable technology and Personal Protective Equipment “PPE”, owns and licenses a portfolio of patents in the GPS and wearable technology space, and is a GSA-approved military and government supplier. The Company’s products are available at its online store, Amazon, and global partners. To find out more about how you can buy or become an authorized reseller of GTX products, contact us info@gtxcorp.com
Remember the 3 W’s to reduce the risks of COVID -Wear a mask, Wash your hands and Watch your distance.
MetAlert (OTC: MLRT) and its subsidiary Level 2 Security occupy a commanding position in the design, development, manufacturing, distribution, sales, and IP licensing of GPS wearable technology, firearm and mobile asset recovery solutions, remote patient monitoring technology, and health data collection. With years of industry expertise and a robust portfolio of patents, MetAlert is the go-to solution provider for government, enterprise and consumers grappling with mobility, cognitive, and spatial awareness challenges, which currently represents approximately 2.9% of the global population. The Company delivers comprehensive turnkey solutions encompassing logistics, hardware, software, and connectivity.
Notable achievements include the groundbreaking GPS SmartSole®, a fusion of Dr. Scholl’s comfort with LoJack’s tracking prowess. It stands as the world’s inaugural invisible wearable tracking device, designed for individuals susceptible to wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. And MyGunAlert the first patented lockable, motion sensitive, firearm recovery device supported by law enforcement.
MetAlert’s subscription-based model thrives on technology innovation fortified by intellectual property safeguards. The company boasts international distribution channels serving customers across 40 countries, alongside its role as a U.S. Military Government contractor. In addition to public health entities, MetAlert caters to municipalities, emergency and law enforcement agencies, private and public educational institutions, assisted living facilities, NGOs, senior care residences, consumers, and small enterprises. Recognizing its capacity within its distribution center and backend subscription processing also presents an opportunity to provide backend services for other subscription based enterprises.
General information, investor relations, wholesale licensing, consumer purchase:
213.489.3019 | Info@MetAlert.com | IR@MetAlert.com | Contact Us
MetAlert.com | Mygunalert.com | Track My Workforce | GPS SmartSole.com
MetAlert United Kingdom– In the UK, MetAlert operates from its London office.
Please contact: Nelson Skip Riddle | Email: NSRiddle@MetAlert.com | Tel: +44 7785 364100
Level 2 Security (Wholly owned subsidiary) Email: contactus@level2sec.com | www.mygunalert.com | www.ifitmoves.com
Forward Looking Statements
This news release contains forward-looking statements. The terms and phrases “expects,” “would,” “will,” “believes,” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by MetAlert considering its experience and perception of current conditions and expected future developments, as well as other factors that MetAlert believes are appropriate in the circumstances. Many factors could cause MetAlert’s actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Certain risk factors that may cause actual results to differ are outlined in MetAlert’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (which may be obtained on the SEC Website). These factors should be considered carefully, and readers should not rely on MetAlert’s forward-looking statements. MetAlert has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required.
Disclaimer: MetAlert does not warrant or represent that the unauthorized use of materials drawn from this document’s content will not infringe the rights of third parties who are not owned or affiliated by MetAlert. Further, MetAlert cannot be held responsible or liable for the unauthorized use of this document’s content by third parties unknown to the company.
Forward Looking Statements
This news release contains forward-looking statements. The terms and phrases “expects,” “would,” “will,” “believes,” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by MetAlert considering its experience and perception of current conditions and expected future developments, as well as other factors that MetAlert believes are appropriate in the circumstances. Many factors could cause MetAlert’s actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Certain risk factors that may cause actual results to differ are outlined in MetAlert’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (which may be obtained on the SEC Website). These factors should be considered carefully, and readers should not rely on MetAlert’s forward-looking statements. MetAlert has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required.
Disclaimer: MetAlert does not warrant or represent that the unauthorized use of materials drawn from this document’s content will not infringe the rights of third parties who are not owned or affiliated by MetAlert. Further, MetAlert cannot be held responsible or liable for the unauthorized use of this document’s content by third parties unknown to the company.